Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, single-center, placebo-controlled, single-blind, first-in-human,
single-ascending dose study with additional multiple-ascending dose cohorts in healthy male
and female volunteers.